EGFR and non-small cell lung carcinoma: Current standard treatment for NSCLC patients with EGFR-sensitive mutations, such as exon 19 deletion (19DEL) and substitution of lysine with arginine in exon 21 (21L858R), involves the use of EGFR–tyrosine kinase inhibitors (TKIs).